What I didn't touch base on much in my above post last night has been briefly discussed, but I don't think the full weight of its annoucement has been taken on board.
GSK analgesics/medicated skin care have had two very interesting JV's/purchases (Novartis JV, Stiegel an acquisition) that are going to be exceptionally promising for OBJ's tech, should these discussions prove successful.
Novartis is a massive powerhouse, dealing in products such as Voltaren....
"Novartis manufactures such drugs as
clozapine(Clozaril),
diclofenac (Voltaren),
carbamazepine(Tegretol),
valsartan (Diovan) and
imatinib mesylate (Gleevec/Glivec). Additional agents include
cyclosporin (Neoral/Sandimmun),
letrozole (Femara),
methylphenidate (Ritalin),
terbinafine (Lamisil), and others."
Stiefel on the other hand is ALL about skincare....
OBJ's specialty....
I'll refer back to 2005 to show just how good - and that was a decade ago...I don't think OBJ tech has stood still....
Last, but definitely not least.
Bodyguard was initially considered a cash drain.
Now it may very we'll be a billion dollar product if it's as good as it seems. (More Info in my previous post above).
So if BG was a drain on cash. With management knowing this. And we have this in our statement:
In my opinion only, this means one thing.
Management are fully comfortable with this. Because there will be CASH coming soon. And over the next many years. And they know it.
They might even hit their performance targets...
Kiwi
(20min delay)